Abstract
The discovery of neuropeptides as signaling molecules with paracrine or hormonal regulatory functions has led to trailblazing advances in physiology and fostered the characterization of numerous neuropeptide-binding G protein-coupled receptors (GPCRs) as potential drug targets. The impact on human health has been tremendous: Approximately 30% of commercial drugs act via the GPCR pathway. However, about 25% of the GPCRs encoded by the mammalian genome still lack their pharmacological identity. Searching for the orphan GPCR endogenous ligands that are likely to be neuropeptides has proved to be a formidable task. Here we describe the mass spectrometry (MS)-based technologies and experimental strategies that have been successful in achieving high-throughput characterization of endogenous peptides in nervous and endocrine systems.
Original language | English (US) |
---|---|
Pages (from-to) | 579-586 |
Number of pages | 8 |
Journal | Trends in Pharmacological Sciences |
Volume | 36 |
Issue number | 9 |
DOIs | |
State | Published - Sep 12 2015 |
Keywords
- bioinformatics
- endogenous peptides
- mass spectrometry
- nervous system
- quantitation
- sequencing
ASJC Scopus subject areas
- Toxicology
- Pharmacology